Skip to main content
Novartis India Limited. logo

Novartis India Limited. — Investor Relations & Filings

Ticker · NOVARTIND ISIN · INE234A01025 LEI · 335800MD8SVYXUDLTP28 BSE.NS Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2026-05-30 Regulatory Filings
Country IN India
Listing BSE.NS NOVARTIND

About Novartis India Limited.

https://www.novartis.com/in-en/

Novartis India Limited focuses on providing innovative healthcare solutions and medicines to address unmet medical needs. The company specializes in therapeutic areas such as cardiovascular, renal, metabolism, immunology, oncology, and neuroscience. Its core activities involve the marketing and distribution of a broad portfolio of prescription drugs and advanced therapies. Novartis India leverages global research and development capabilities to introduce cutting-edge treatments, including biologics and gene therapies, aimed at improving patient outcomes. The company emphasizes digital transformation and data-driven insights to enhance healthcare delivery and patient access. By collaborating with healthcare professionals and institutions, Novartis India seeks to transform the practice of medicine and provide sustainable health solutions across diverse patient populations.

Recent filings

Filing Released Lang Actions
Intimation of sending Reminder to respective shareholders for transfer of Shares of Novartis India Limited ("The Company") to Investor Education & Protection Fund ("IEPF").
Regulatory Filings Classification · 85% confidence The document is a formal letter filed with the stock exchange under SEBI LODR Regulation 30, enclosing specimens of reminder letters and newspaper advertisements for transfer of unclaimed shares to the IEPF. It contains no financial statements or dividend payment details, no management changes, and no report publication. It is a generic compliance/regulatory disclosure to the exchange. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-30 English
Annual Secretarial Compliance Report for the financial year ended March 31, 2026.
Regulatory Filings Classification · 85% confidence The document is an Annual Secretarial Compliance Report submitted by the company secretary and practicing firm under SEBI LODR Regulation 24A, consisting primarily of a compliance certificate/attestation rather than substantive financial statements or corporate disclosures of a distinct filing type. It is not an annual or quarterly financial report, proxy materials, or management narrative, but a regulatory compliance certification. Under the Certification Rule, officer certifications and compliance attestations belong in the Regulatory Filings (RNS) category.
2026-05-22 English
Declaration of Voting Results of the Postal Ballot of Novartis India Limited ("The Company") and Scrutinizer''s Report.
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is a formal filing to the stock exchange reporting the declaration of voting results of a postal ballot and attaching the Scrutinizers’ Report. It does not contain financial statements or an annual/interim report, nor is it simply announcing an upcoming report; rather, it provides the official vote tallies for a shareholder resolution. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-05-19 English
Declaration of Voting Results of the Postal ballot of Novartis India Limited ("The Company") and Scrutinizer''s report.
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is an official stock exchange filing declaring the postal ballot voting results and enclosing the Scrutinizers’ Report pursuant to SEBI Listing Regulations and the Companies Act. It does not itself propose resolutions, announce management changes, or provide a financial report, but simply reports shareholders’ votes. This corresponds exactly to “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-05-19 English
Newspaper publication of the corrigendum to the Notice of Postal Ballot for the appointment of Ms. Gowree Gokhale as an Independent Director dated April 16, 2026
Regulatory Filings Classification · 65% confidence The document is a composite of multiple short regulatory announcements: an intimation to the stock exchange of a newspaper advertisement corrigendum to a postal ballot notice, a fund addendum notice, and extracts of audited financial results for different entities. There is no single cohesive full annual or interim report, proxy statement or earnings release; rather, these are miscellaneous compliance filings under listing regulations. As such, it best fits the fallback category for general regulatory filings (RNS).
2026-05-16 English
Corrigendum to the Notice of Postal Ballot issued on April 16, 2026, for the appointment of Ms. Gowree Gokhale (DIN: 09351661) as an Independent Director.
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice of a postal ballot (including a corrigendum) circulated to shareholders under the Companies Act and SEBI Listing Regulations, complete with voting instructions, explanatory statements, cut-off dates, resolution details, and e-voting procedures. It is not a results announcement, financial report, or simple board change announcement but rather a solicitation of shareholder votes through postal ballot. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-15 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.